Collegium (COLL) to Report Q1 Earnings: Here's What to Expect [Yahoo! Finance]
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER [Yahoo! Finance]
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.